LAMP-vax was originally developed as a novel way of improving the adaptive immune response upon vaccination to human papilloma virus and human immunodeficiency virus antigens. The original studies were conducted by ITI scientific co-founder Dr. Tom August and colleagues at Johns Hopkins University, including Dr. Drew Pardoll and Dr. T-C Wu, among others.

ITI collaborated with Dr. August’s labs and designed a prototype immunotherapeutic for HIV. The company held a pre IND meeting with the FDA.

In addition to applications in HPV and HIV, LAMP-vax formulations have been developed and tested by academic groups as preventative and therapeutic vaccines for rabies, yellow fever, dengue fever, SARS, and hepatitis C.